Abstract library

620 results for "serum miRNA expression".
#674 Serum miRNA Expression in Small Intestine Neuroendocrine Tumors and Biological Function of miR-196a in Neuroendocrine Tumor Cells
Introduction: MicroRNAs (miRNAs), post-transcriptional regulators, function either as tumor suppressors or oncogenes. We recently identified five upregulated and four downregulated miRNAs in small intestinal neuroendocrine tumor (SI-NET) tissue. We then started new analysis on body fluids to detect tumor signatures using patients’ serum.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Rakan Naboulsi
Authors: Naboulsi R, Li S C, Cui T, Öberg K, ...
#807 MicroRNA Expression in Serum of Small Intestine Neuroendocrine Tumor Patients and miR-196a Biological Function in Neuroendocrine Tumor Cells
Introduction: We have previously identified five upregulated and four downregulated miRNAs in small intestinal neuroendocrine tumor (SI-NET) tissue. We extended our analysis to serum samples of SI-NET patients to depict miRNAs functions.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Su-Chen Li
Authors: Li S C, Khan M S, Caplin M, Öberg K, ...
#585 Global microRNA profiling of small intestine neuroendocrine tumors (SI-NETs) and establishment of a method to study serum microRNA expression from the same tumors
Introduction: MicroRNAs (miRNAs) are important post-transcriptional regulatorsin biological processes and function either as tumor suppressors or oncogenes.
Conference:
Category: Basic
Presenting Author: Su-Chen Li
Authors: Li S C, Martijn C, Essaghir A, Lloyd R, ...
#727 Serum Levels of Chromogranin A Were Not Elevated in Patients with Insulinomas
Introduction: According to ENETS and NANETS Consensus Guidelines, Chromogranin A (CgA) is the most practical and useful serum tumor marker in NET patients (pts), including pancreatic NETs. Many studies suggested that test of blood CgA should be mandatory for NET diagnosis.
Conference: 10th Annual ENETS Conference (2013)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. X-W Qiao
Authors: Qiao X W, Qiu L, Liu B, Song Y L, ...
#1269 CEA Level, Radical Surgery and CD56 Expression Are Prognostic Factors for Patients with Locoregional Gastrin-independent GNET
Introduction: Gastrin-independent gastric neuroendocrine tumors (GNETs) are highly malignant. Radical resections and lymphadenectomy are considered to be the only possible curative treatment for these tumors. However, the prognosis of gastrin-independent GNETs is not well defined.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Yuan Li
Authors: Li Y, Zhao H, Cai J, ...
#20 Paraneoplastic antigen Ma2 (PNMA2) auto-antibodies as biomarkers for early small intestine neuroendocrine tumors detection
Introduction: Small intestine neuroendocrine tumors (NETs) comprise well-differentiated NET (benign carcinoid), well-differentiated neuroendocrine carcinoma (malignant carcinoid) and poorly differentiated neuroendocrine carcinoma (NEC). The majority of NET patients have developed liver metastases at the time of diagnosis and surgery is then seldom curative. Novel predictive, diagnostic and prognostic markers are thus needed to improve our capabilities to diagnose and cure these tumors. We have previously identified six novel marker genes for neuroendocrine tumor cells by using Affymetrix microarrays and advanced bioinformatics. One of this markers, the paraneoplastic antigen Ma2 (PNMA2), which is normally expressed only in nervous tissue, can in the process of carcinogenesis be detected in tumors located outside the nervous system. The finding that Ma2 is expressed in small intestine neuroendocrine primary tumors and their metastases made it interesting to screen whether antibodies against Ma2 are present in the serum of NET patients.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: PhD Valeria Giandomenico
Authors: Cui T, Elgue G, Li S C, Hurtig M, ...
#1412 MiR-196a Is Specifically Regulated in FDG-PET Positive and Negative Small Intestinal Neuroendocrine Tumor Patients at Late Stage of Disease
Introduction: This collaborative research plan aims at elucidating the glycolytic metabolism in advanced FDG-PET positive (+) and FDG-PET negative (-) small intestinal neuroendocrine tumor (SI-NET) patients treated with Lutetium peptide receptor radionuclide therapy (177Lu-PRRT).
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: PhD Valeria Giandomenico
#942 Ileal Neuroendocrine Well-Differentiated Tumors: Prognostic factors with Focus on Loss of Succinate Dehydrogenase (SDHB) Expression
Introduction: Ileal Neuroendocrine Well-Differentiated Tumors (INWDT) are the most common neuroendocrine neoplasms in the gastrointestinal tract. Gene mutations of SDH complex drive pathogenesis of cancer cells through their role in angiogenesis and cell proliferation.
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Massimo Milione
#1545 In Vivo Expression of Survivin and XIAP in Medullary Thyroid Carcimoma
Introduction: Medullary thyroid carcinoma (MTC) accounts for approximately 5 % of all thyroid malignancies. Although surgery remains the first line therapy with curative intention, for advanced MTC current chemotherapeutic regimes do not provide promising results. Consequently, the identification of biologically relevant biomarkers that are associated with MTC progression may provide novel therapeutic targets.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr. Andreas Krieg
Keywords: MTC, IAP, survivin, XIAP
#88 EpCam expression and detection of circulating tumor cells in neuroendocrine tumors
Introduction: Using the CellSearchTM system, circulating tumor cells (CTCs) can be reproducibly enumerated according to expression of EpCAM and cytokeratins 8, 18 or 19 and the absence of the haemopoietic marker CD45. The number of CTCs detected in 7.5 mls blood has been shown to correlate with prognosis in breast, colon and prostate cancer and can predict response to therapy. Neuroendocrine tumors (NETs) have not previously been reported to express EpCAM and have not been systematically assessed for presence of CTCs. We have therefore explored the expression of EpCAM in NETs and the detection of NET cells in the circulation.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss on any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team